Dr Ticiana Leal, MD, outlines the specific demographic and diagnosis of a patient with small cell lung cancer.
A 61-Year-Old Man With Small Cell Lung Cancer
Dr Ticiana Leal, MD, comments on the treatment given, the effectiveness of treatment, and the future prognosis of this patient with small cell lung cancer.
Dr Ticiana Leal, MD, lists the treatment options associated with first-line therapy and its relation to platinum sensitivity.
Dr Ticiana Leal, MD, discusses the role of topotecan and lurbinectedin as novel agents in second-line therapy for small cell lung cancer.
Dr Ticiana Leal, MD, describes the choice to prescribe lurbinectedin in the second-line setting for the patient as well as her personal experience with the drug.
Dr Ticiana Leal, MD, highlights the approvals of new regiments in small cell lung cancer. However, she discusses the struggles physicians currently face, such as identifying predictive biomarkers used to select patients who may respond well to new treatment regiments.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
